Risk adjusted net present value: What is the current valuation of Enliven Therapeutics’s ELVN-002?

ELVN-002 is a small molecule commercialized by Enliven Therapeutics, with a leading Phase I program in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

4 Steps to Patient-Centric Incident Response in Healthcare

Mike Donahue, Chief Delivery Officer, CloudWave The healthcare industry reported more ransomware attacks than any other critical infrastructure sector in 2023. With the escalation of

November 6, 2024

FDA warns industry of ‘fraudulent’ third-party data in device applications

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The Food and Drug Administration

February 21, 2024

China grants approval for GenFleet’s fulzerasib to treat lung cancer

The treatment is indicated for NSCLC patients who have received a minimum of one systemic therapy previously. Credit: 19 STUDIO/Shutterstock. The National Medical Products Administration

August 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.